We observed significant differential expression between cancerous and non-cancerous tissues, with higher PTPN23 levels noted in esophageal adenocarcinoma (ESCA), stomach adenocarcinoma (STAD), low-grade glioma (LGG), and colon adenocarcinoma (COAD), while other cancers displayed low expression levels(Fig 7B). This evidence concerns the gene PTPN23 and central nervous system cancer.